501 CANAL BLVD., RICHMOND, CA
Sangamo Therapeutics Enters Underwriting Agreement for Stock Offering
Other Events
Earnings Release
Reports Recent Business Highlights And Third Quarter 2025 Financial Results
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Changes in Board, Management or Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement
Automatic Shelf Registration Statement